

Medytox, Inc. '25.Q1 earnings release

Disclaimer

All financial information contained in this document is based on consolidated K-IFRS. This document contains information and financial data that have not been audited by an independent auditor. The reason for our earnings release announcement prior to an independent auditor's audit is to communicate our financial results to the market and investors in a timely manner. Therefore, the information and financial data contained in this document are subject to change upon an independent auditor's audit.

The company does not make any representation or warranty, as to the accuracy or completeness of the information contained in this material. And we are not responsible for the update on content that described current facts.

Earnings: '25 Q1 Results (Consolidated)

- Sales in Q1 hit KRW 64 billion, the highest ever seen in Q1, boosted by high demand for toxin products both at home and abroad, turning an operating profit of KRW 5.5 billion compared to a year earlier. SG&A expenses remained high in Q1, largely due to increased legal costs.

(Unit: KRW 100mn)	'25 Q1	'24 Q4	'24 Q1	Growth	
				Q/Q	Y/Y
Sales	640	552	546	16%	17%
COGS	259	220	215	18%	20%
(%)	40%	40%	39%	1%p	1%p
Gross margin	381	332	331	15%	15%
SG&A expense	326	322	340	1%	-4%
Operating income	55	9	-9	511%	Turned a Profit
(%)	9%	2%	-2%	7%p	10%p
Other revenue	10	131	23	-92%	-57%
Other expense	19	133	25	-86%	-24%
Pre-tax income	45	7	-11	543%	Turned a Profit
Tax	11	-17	4	-	175%
Net income	33	24	-15	38%	Turned a Profit
(%)	5%	4%	-3%	1%p	8%p

Earnings: Sales Breakdown

◆ Regional Sales (Q1)

(Unit: KRW 100mn)		'25 Q1	'24 Q4	'24 Q1	Q/Q	Y/Y
Export		399	335	355	19%	12%
	Asia	187	139	193	35%	-3%
	Europe	7	8	23	-4%	-68%
	Oceania	0.7	0.3	0.8	116%	-16%
	Middle East	7	18	33	-62%	-79%
	Africa	-	-	-	-	-
	America	197	170	105	16%	88%
Domestic		240	217	191	11%	26%
Total		640	552	546	16%	17%

Earnings: Sales Breakdown

◆ Product Sales (Q1)

(Unit: KRW 100mn)		2025 Q1	2024 Q4	2024 Q1	Q/Q	Y/Y
Export		399	335	355	19%	12%
	Toxins	158	129	136	23%	16%
	Fillers	175	138	170	27%	3%
	Others	66	68	49	-4%	34%
Domestic		240	217	191	11%	26%
	Toxins	171	136	96	26%	79%
	Fillers	44.4	53.9	48	-18%	-8%
	Others	25	27	47	-7%	-47%
Total		640	552	546	16%	17%

Appendix: Balance Sheet Summary

(Unit: KRW 100mn)	2025 Q1	2024	Net Change
Asset			
- Current Asset	1,759	1,866	(107)
- Non Current Asset	4,271	4,286	(15)
Total Asset	6,030	6,152	(122)
Liability			
- Current Liability	1,120	1,176	(55)
- Non Current Liability	263	268	(5)
Total Liability	1,384	1,444	(60)
- Paid in Capital	39	39	0
- APIC	1,481	1,481	0
- Others-T/S	(1,116)	(1,015)	(101)
- OCI	(112)	(92)	(20)
- Retained Earnings	4,325	4,252	73
- Controlling Interest	4,616	4,665	(49)
- Non-controlling interest	30	43	(13)
Total Capital	4,647	4,708	(61)
Total Liability & Capital	6,030	6,152	(122)
-Gearing Ratio	30%	31%	